rosuvastatin + daridorexant

**rosuvastatin + daridorexant** is an investigational combination of two small molecule drugs: **rosuvastatin**, a statin, and **daridorexant** (development code **ACT-541468**), a dual orexin receptor antagonist. Rosuvastatin is primarily an HMG-CoA reductase inhibitor that reduces cholesterol synthesis in the liver, leading to lowered LDL cholesterol and reduced risk for cardiovascular events. Daridorexant selectively antagonizes orexin receptor type 1 and type 2, which are involved in the regulation of sleep and arousal, and is approved for treating insomnia. Research appears limited to pharmacokinetic interactions; there is no evidence of clinical development of this specific combination for a shared therapeutic indication.

Brand names

CrestorEzallor SprinkleQuviviq

Other names

rosuvastatin calciumdaridorexant hydrochlorideACT-541468ACT541468ACT 541468